USP22 and hepatocellular carcinoma: In summary, our study demonstrated that USP22 promotes the growth of hepatocellular carcinoma and resistance to Sorafenib‐induced ferroptosis by removing ubiquitin moieties from non‐histone protein CDK11B and histone H2B.